							Referral Status: MRN:							
						Patien	New referral t preferred clinic:	Order ch	nange	Order F	Renewal			
						ration	represented cinite.	1						
Infl	ivimah Unchac	ific	yd Dla	n of Tr	oatmont for F)orm	atology							
	iximab Unspec ENT DEMOGRAPH			11 01 11	eatiment for L	<i>J</i> EIIII	latology							
	of Referral:	165.				Patie	ent's Phone:							
	ent Name:					Address:								
Date of Birth:							City, State, Zip:							
							G Gender: Allergies: See list NKDA							
	GNOSIS: (PLEASE CO			2 ND AND										
	L40.5 - Psoriatic													
	L40 Psoriasis			. ,										
	Other:													
REQ	UESTED DOCUMEN	ITA ⁻	TION:		PREVIOUS ADMI	NISTR	ATION: HAS THIS	PATIENT T	AKEN THI	S MEDICAT	ION			
1	nsurance information				IF NO:	IF YES:								
2	Most recent History & Physical				PLEASE STATE	LAST INFUSION DATE:								
3	Full medication list				REQUIRED WASHOUT FROM PREVIOUS	NEXT INFOSION DATE.								
4	<u> </u>	Tried and failed therapies				IF ORDER CHANGE:								
5	REQUIRED: TB screen					Continue current ord			er until insurance approved					
6	HBV screening/labs as		uired by p	payor		Continue durient order diffirmisarance approve								
	DICATION ORDERS: Patient may be ineligible to red		fl:: i:-		:h:-h:fh::-fh:							to me of		
	Patient may be ineligible to rec ew-onset or deterioration neur					process,	antifungal therapy, active f	ever and/or susp	pected infectio	n, new or worser	ing symp	toms or		
	MEDICATION TO BE AD	_			•	INISTR	ATION AS SELECTE	D						
Prem	edication with antihistam	nines	, acetam	ninophen, a	nd/or corticosteroids n	nay be	considered to prevent	t infusion-rela	ated reaction	ıs.				
	Diphenhydramine		25mg	50mg			Acetaminophen	325mg	500m(650mg		1000mg		
ıv	Methylprednisolone		40mg	125mg	Other:		Famotidine	20mg	40mg					
I IV	Famotidine		20mg	40 mg			Diphenhydramine	25mg	50mg					
	Other:			-		PO	Fexofenadine	60mg	180mg	3				
SPEC	CIFIC MEDICATION:						Cetirizine	10mg	·	•				
	Remicade		Anv i	inflixim	ab		Loratadine	10mg						
	Avsola	- July Hillouine					Other:		•					
	biosiiiilai iila					FREC	QUENCY:	•			-			
	Ponflovio used accordin					Induction to be completed at week 0, week 2, and week 6,						and		
DOS	I paver guigeiii			<u>nes</u>	then every 8 weeks thereafter									
	5mg/kg diluted in NS infused IV per step protoc				col over 2 hours	Maintenance every 8 weeks								
	Other:							Infuse every weeks						
	May utilize expedited in	nfusi	on per p	rotocol to i	un over 1 hour as tole	rated]							
*1.561:5	J :imab daga <1000ma	: 21	FOrm! NC	daaaa > 1	000mm in E00ml NC	SPF	CIAL/LAB ORDERS	S:						
	kimab doses <1000mg Dmg in 1000ml NS (max					<u> </u>	<u> </u>							
	, , , , , , , , , , , , , , , , , , ,				,	<u> </u>	J							
Pres	criber confirms that the	pati	ent has I	been evalua	ated and screened for	the pre	sence of hepatitis B	virus (HBV) p	rior to initia	ting treatmer	it. Pres	criber to		
					nptoms of HBV and TE									
						Refills x 12 months unless noted otherwise here:								
LINE	USE/CARE ORDER	c.				ADVERSE REACTION & ANAPHYLAXIS ORDERS:								
LINE	Start PIV/Access CV					@13054384A@								
							Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing							
Flush device per facility standard flushing procedure							F600 44.50 C0 200 C							
Provide nursing care per Palmetto Infusion Nursing Procedure and post procedure observation if indicated						es	our website or scan				⊕.4			
DDE	SCRIBER INFORMA			ii indicate	ea									
	VIDER NAME:		IV.				PHONE:							
	RESS:						FAX:							
	, STATE, ZIP:						NPI:							
	SCRIBER SIGNATUR	RF: L	No sta	mn signa	tures)		1.4			DATE:				
TIVE	SCHIDEN SIGNATUR	re- (rro sta	mb aigile	tures _j					DATE.				
	D:	/D :	1				0 1	***	-					
	Dispense as wr	ıtten	/Brand	medically	necessary			Substitution	on permitte	a				



Checklist for referrals to Palmetto Infusion: Fax referral to 1.866.872.8920

Patient demographics - a	ddress, p	ohone n	umber, S	S#, etc.
Insurance information – co	opy of th	e card(s	s) if poss	ible
Plan of Treatment/Orders				
Most recent physician offi failed therapies – all insur pre–authorization require Medicare/Medicaid HMO	ance cor	mpanies	that red	
Any lab results or other dis support the diagnosis.	agnostic	proced	ures to	

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

www.PalmettoInfusion.com